Citations 1
SUN-592 Prevalence of Dysglycemia Based Chronic Disease in Iranian Adults
Nasir, Ayesha Nayab, Dehghani, Fatemah, Saeidifard, Farzane , Ghannam, Mohammad, Almakadma, Abdul Hakim , Idries, Iyad Yousef Mohammad, Qobali, Mina, Esteghamat, Alireza, Martinez, Ramfis Nieto-, Mechanick, Jeffrey I. , Nasir, Ayesha Nayab, Dehghani, Fatemah, Mechanick, Jeffrey I.
Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available
Abstract Disclosure: A. Nasir: None. F. Dehghani: None. F. Saeidifard: None. M. Ghannam: None. A. Almakadma: None. I. Idries: None. A. Esteghamat: None. R. Nieto- Martinez: None. J.I. Mechanick: None. Background: The Dysglycemia-Based Chronic Disease (DBCD) multi-morbidity care model was developed by American Association of Clinical Endocrinology to address the requirement for preventive care measures to reduce the impact of type two diabetes (T2D ) and its complications. The DBCD model consists of four distinct stages including: insulin resistance, prediabetes, T2D and vascular complication spectrum. This study assesses the prevalence and associated risk factors for each of the four DBCD stages in Iranian adults. Methods: From February 2002 to March 2020, 10,087 participants who attended clinic of Vali-Asr Hospital, Tehran, Iran, were evaluated. In total, 3,465 (34.3%) men with median age of 54.47 years and 6,629 (65.67%) women with median age of 50.2 years were included. A 10 ml blood sample was collected after an overnight fast, centrifuged, and stored at -70°C for lab evaluation to measure fasting blood sugar (FBS). Hemoglobin A1c was measured using high-performance liquid chromatography, while fasting and post-prandial glucose were assessed using enzymatic colorimetric methods. Results: Stage 1 was found in 19.7% of the population (23.2% in women and 13.1% in men), stage 2 in 17.8% of the population (19.3% in women and 14.8% in men), stage 3 in 31.4% of the population (28.2% in women and 37.5% in men), and stage 4 in 21.3% of the population (16.2% in women and 30.9% in men). DBCD stages increased significantly with age (stage 1=43.12, stage 2=51.24, stage 3=54.89, stage 4=61.51, P-value <0.01). All DBCD stages were associated with hypertension (stage 1: OR=3.07, stage 2: OR=5.08 ,stage 3: OR=7.87 and stage 4: OR=17.17) dyslipidemia (stage 1: OR=2.85, stage 2: OR=2.68, stage 3: OR=8.32, and stage 4: OR=7.66)and metabolic syndrome (stage 1: OR=14.04, stage 2: OR=21.95, stage 3: OR=32.50, and stage 4: OR=42.54). Conclusion: The findings of the current study further support the importance of the DBCD model in early detection and prevention of dysglycemia and their associated complications. Presentation: Sunday, July 13, 2025